VERTEX PHARMACEUTICALS INC / MA — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VERTEX PHARMACEUTICALS INC / MA filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $651.63M | Feb 15, 2018 |
| FY2017 | Sep 30, 2017 | $578.17M | Feb 15, 2018 |
| FY2017 | Jun 30, 2017 | $544.14M | Feb 15, 2018 |
| FY2017 | Mar 31, 2017 | $714.72M | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $458.71M | Feb 15, 2018 |
| FY2017 | Sep 30, 2016 | $413.78M | Feb 15, 2018 |
| FY2017 | Jun 30, 2016 | $431.61M | Feb 15, 2018 |
| FY2017 | Mar 31, 2016 | $398.08M | Feb 15, 2018 |
| FY2016 | Dec 31, 2015 | $417.94M | Feb 23, 2017 |
| FY2016 | Sep 30, 2015 | $309.82M | Feb 23, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.00B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $11.02B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $9.87B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $8.93B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $7.57B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $1.63B | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $1.54B | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $1.52B | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $1.52B | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $1.41B | Feb 11, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.95B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($535.60M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.62B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $3.32B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $2.34B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $604.19M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $667.43M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $837.27M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $602.75M | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $583.23M | Feb 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.17B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($232.90M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.83B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.31B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $2.78B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $745.79M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $672.24M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $718.03M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $720.22M | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $551.47M | Feb 11, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.64B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $22.53B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $22.73B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $18.15B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $13.43B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $11.75B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $8.32B | Feb 11, 2021 |
| FY2019 | Jan 1, 2019 | $6.26B | Feb 13, 2020 |
| FY2019 | Dec 31, 2018 | $6.25B | Feb 13, 2020 |
| FY2018 | Jan 1, 2018 | $3.56B | Feb 13, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.98B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $6.12B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $5.15B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $4.24B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.33B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $3.07B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $2.23B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.81B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.50B | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $1.56B | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.67B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $16.41B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $17.58B | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $13.91B | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | $10.10B | Feb 13, 2025 |
| FY2023 | Dec 31, 2020 | $8.69B | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | $6.09B | Feb 10, 2023 |
| FY2021 | Dec 31, 2018 | $4.44B | Feb 9, 2022 |
| FY2018 | Dec 31, 2017 | $2.03B | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $1.16B | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 14 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 12 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 9 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | 3 | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | 2 | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | 2 | Feb 11, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 13 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 12 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 9 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | 3 | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | 2 | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | 2 | Feb 11, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.08B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $4.57B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $10.37B | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $10.50B | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | $6.80B | Feb 13, 2025 |
| FY2023 | Dec 31, 2020 | $5.99B | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | $3.11B | Feb 10, 2023 |
| FY2021 | Dec 31, 2018 | $2.65B | Feb 9, 2022 |
| FY2020 | Dec 31, 2017 | $1.67B | Feb 11, 2021 |
| FY2019 | Dec 31, 2016 | $1.18B | Feb 13, 2020 |